Federal Register #E1452026

License Opportunity for Matched Patient-Derived 3D IDH-Mutant Glioma Cell Lines (403L and 403H) from NCI

This opportunity from the National Cancer Institute (NCI), part of the National Institutes of Health, offers licensing for unique patient-derived 3D IDH-mutant glioma cell lines (403L and 403H). - Government Buyer: - National Institutes of Health (NIH) - National Cancer Institute (NCI) - OEM: - National Cancer Institute (NCI) - Products Requested: - Matched patient-derived 3D IDH-mutant glioma cell lines - 403L: Pre-malignant transformation (WHO grade 2) - 403H: Post-malignant transformation (WHO grade 4) - Part numbers: 403L, 403H, E1452026 - Quantities: Not specified (licensing for research use) - Notable Requirements: - Cell lines retain endogenous IDH1 R132H mutation - 3D spheroid growth; 403H exhibits increased invasiveness and temozolomide-associated hypermutation - Intended for oncology and neurology research (tumor progression, metabolism, treatment resistance) - Highly curated, clinically relevant models for advanced research - No direct purchase; this is a licensing opportunity for research materials - Competitive advantages include clinical relevance, rigorous curation, and superior diagnostic precision

Description

The National Cancer Institute (NCI) seeks licensees for matched patient-derived 3D Isocitrate Dehydrogenase (IDH)-mutant glioma cell lines, 403L and 403H, generated from the same patient before and after malignant transformation from WHO grade 2 to WHO grade 4 disease. These cell lines provide a research tool to study IDH-mutant glioma progression, temozolomide-associated hypermutation, invasion, metabolism, and treatment resistance. The 403H line shows increased invasive behavior and tumor mutational burden compared to 403L, making these materials valuable for cancer research and therapeutic development.

View original listing